Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM BICARBONATE vs COLYTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium bicarbonate dissociates to provide bicarbonate ion, which buffers excess hydrogen ions in the blood, increasing p H and reversing acidosis.
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Treatment of metabolic acidosis,Cardiac arrest associated with hyperkalemia or tricyclic antidepressant overdose,Alkalinization of urine to prevent nephrotoxicity from certain drugs (e.g., methotrexate, sulfonamides),Adjuvant in treatment of severe diarrhea (off-label),Treatment of distal renal tubular acidosis (off-label)
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
For metabolic acidosis: 50-150 m Eq intravenously over 4-8 hours, dose adjusted based on base deficit or serum bicarbonate. For cardiac arrest: 1 m Eq/kg intravenously initially, then 0.5 m Eq/kg every 10 minutes. For urinary alkalinization: 325-2000 mg orally every 6 hours, titrate to urine p H 7-8.
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
5-6 hours in normal renal function; prolonged in renal impairment (up to 15-20 hours)
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Sodium bicarbonate is not metabolized; it dissociates to bicarbonate and sodium. Bicarbonate is rapidly converted to carbon dioxide by carbonic anhydrase in erythrocytes and renal tubules, and CO2 is excreted via lungs.
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Renal: >99% as bicarbonate; minimal biliary/fecal elimination
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
<1% (not significantly protein bound)
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
0.3-0.4 L/kg (distributes primarily in extracellular fluid)
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Oral: ~100% (but rapid conversion to CO2 in stomach may reduce effective systemic absorption)
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
No specific dose adjustment required; monitor sodium and fluid status. In severe renal impairment (GFR <10 m L/min), use with caution due to risk of volume overload and metabolic alkalosis. Not removed by hemodialysis.
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
No dosage adjustment necessary for hepatic impairment. Use with caution in severe hepatic impairment due to potential for fluid overload and electrolyte disturbances.
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Metabolic acidosis: 1-2 m Eq/kg intravenously over 1-2 hours, repeat based on blood gas. Cardiac arrest: 1 m Eq/kg intravenously initially, may repeat 0.5 m Eq/kg every 10 minutes. Urinary alkalinization: 1-2 m Eq/kg orally every 6 hours, adjust to urine p H.
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
Use with caution due to increased risk of fluid overload and electrolyte imbalances. Start at lower end of dosing range and titrate based on response and renal function. Monitor serum sodium, bicarbonate, and renal function frequently.
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
In cardiac arrest, routine use is not recommended; may cause paradoxical intracellular acidosis, hyperosmolality, and decreased tissue oxygen delivery.
None
Risk of metabolic alkalosis with excessive use,Fluid overload due to sodium content, especially in heart failure, renal impairment, or cirrhosis,Hypocalcemia and reduced ionized calcium leading to tetany,Extravasation risk; intravenous administration should be via central line for concentrated solutions,Monitor serum electrolytes, p H, and calcium during therapy
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Metabolic alkalosis,Respiratory alkalosis,Hypocalcemia (unless used to treat cardiac arrest),Severe pulmonary edema or hypertension,Patients losing chloride from vomiting or gastrointestinal suction
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
High-sodium foods may compound sodium load. Avoid excessive milk or dairy intake (risk of milk-alkali syndrome). Can interfere with iron absorption; take iron supplements 2 hours apart. No specific food restrictions beyond balanced diet.
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
Sodium bicarbonate is generally considered low risk. No evidence of teratogenicity. Use during pregnancy is acceptable if clinically indicated.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
Sodium bicarbonate is excreted into breast milk in small amounts. M/P ratio is not established. Considered compatible with breastfeeding, but monitor infant for metabolic alkalosis risk.
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
Pregnancy may increase volume of distribution and renal clearance, potentially requiring higher doses. However, standard dosing is usually sufficient; titrate to acid-base balance.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
Contains 119 m Eq sodium per 3.8 g (50 m Eq base). Use with caution in heart failure, hypertension, or renal impairment. Rapid infusion can cause hypernatremia, decreased ionized calcium, and tetany. Do not mix with calcium-containing solutions or in the same IV line as catecholamines. In metabolic acidosis, correct only partially (to p H 7.2) to avoid rebound alkalosis. Not first-line for cardiac arrest except in known hyperkalemia or overdose.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
Do not take with milk or dairy products as it may cause milk-alkali syndrome.,Avoid taking within 2 hours of other medications as it may affect absorption.,Do not use as an antacid for more than 2 weeks unless directed by a doctor.,Seek emergency care if you have severe stomach pain, vomiting, or blood in vomit/stool.,Monitor for signs of alkalosis: muscle twitching, hand tremor, confusion, slow breathing.,Inform your doctor if you have high blood pressure, heart failure, or kidney disease.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
"Mycophenolic acid, a prodrug of mycophenolate mofetil, undergoes enterohepatic recirculation and is absorbed in the stomach and proximal small intestine. Sodium bicarbonate, by raising gastric pH, can reduce the dissolution and absorption of mycophenolic acid, leading to decreased systemic exposure and potentially reduced immunosuppressive efficacy. This interaction may increase the risk of transplant rejection when used concurrently."
"Sodium bicarbonate, an alkalizing agent, can increase the gastric pH, which may reduce the dissolution and absorption of topically administered clobetasol propionate if swallowed inadvertently. However, this interaction is not clinically significant for topical application, as systemic absorption of clobetasol is minimal. The theoretical decrease in bioavailability is unlikely to affect efficacy or safety."
"Perphenazine, a phenothiazine antipsychotic, can reduce the absorption of sodium bicarbonate by delaying gastric emptying and increasing gastrointestinal transit time. This results in decreased systemic availability of bicarbonate, potentially attenuating its alkalinizing effect and compromising its efficacy in conditions requiring urinary alkalinization or systemic acidosis correction."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM BICARBONATE vs COLYTE, answered by our medical review team.
SODIUM BICARBONATE is a Alkalinizing Agent that works by Sodium bicarbonate dissociates to provide bicarbonate ion, which buffers excess hydrogen ions in the blood, increasing p H and reversing acidosis.. COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM BICARBONATE and COLYTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM BICARBONATE is: For metabolic acidosis: 50-150 m Eq intravenously over 4-8 hours, dose adjusted based on base deficit or serum bicarbonate. For cardiac arrest: 1 m Eq/kg intravenously initially, then 0.5 m Eq/kg every 10 minutes. For urinary alkalinization: 325-2000 mg orally every 6 hours, titrate to urine p H 7-8.. The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM BICARBONATE and COLYTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM BICARBONATE is classified as Category A/B. Sodium bicarbonate is generally considered low risk. No evidence of teratogenicity. Use during pregnancy is acceptable if clinically indicated.. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.